AbbVie Inc.
AbbVie Inc. (ABBV): 177 pipeline candidates · 46 upcoming catalysts · ~8 mo cash runway · 267 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
8.2 months
N/A
Lead: Phase 1/Phase 2
177 candidates
46 upcoming, next in ~10d
0 buys · 5 sells (180d)
A transparent, data-derived signal for AbbVie Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$390.8B
Cash
$9.4B
Quarterly Burn
$6.0B
Runway
8.2 mo
Revenue
$15.0B
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (177 candidates)
| Drug | Phase |
|---|---|
| [14C]ABT-199 | Phase 1 |
| abbv-101 | Phase 1 |
| ABBV-142 | Phase 1 |
| abbv-1451 | Phase 1 |
| abbv-1758 | Phase 1/Phase 2 |
| ABBV-181 | Phase 1 |
| ABBV-295 | Phase 1 |
| ABBV-319 | Phase 1 |
| abbv-324 | Phase 1 |
| ABBV-368 | Phase 1 |
Showing 10 of 177 candidates. Sign up for full pipeline.
Upcoming Catalysts (46)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
4,057
Total value held
$284.52B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 229,760,648 | $49.97B |
| blackrock, inc. | 150,749,625 | $32.79B |
| state street corp | 81,217,516 | $17.66B |
| vanguard portfolio management llc | 49,523,078 | $10.77B |
| geode capital management, llc | 46,737,581 | $10.14B |
| morgan stanley | 38,016,774 | $8.27B |
| bank of america corp /de/ | 23,936,943 | $5.21B |
| fmr llc | 21,762,703 | $4.73B |
| northern trust corp | 21,211,382 | $4.61B |
| goldman sachs group inc | 16,437,679 | $3.58B |
Showing top 10 of 4,057 institutional holders of AbbVie Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in AbbVie Inc.'s pipeline?
AbbVie Inc. (ABBV) has 177 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is AbbVie Inc.'s lead drug candidate?
AbbVie Inc.'s most advanced tracked candidate is [14C]ABT-199 (Phase 1) for Relapsed/Refractory Non-Hodgkin's Lymphoma.
What is AbbVie Inc.'s next catalyst?
AbbVie Inc.'s next tracked catalyst is a Phase1_Start event — "Phase 1 Start: A Phase 1 Open-Label, Two-Period Study to Evaluate the Impact of Multiple Doses of Itraconazole on t" — expected June 28, 2026.
What is AbbVie Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, AbbVie Inc. has approximately 8.2 months of cash runway.
What is AbbVie Inc.'s market capitalization?
AbbVie Inc.'s market capitalization is approximately $390.8B.
Get the full picture on AbbVie Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.